Eventide US Market ETF (ESUM)

The Eventide US Market ETF (ESUM) is Eventide Asset Management’s broadly diversified U.S. equity fund, offering exposure across all market capitalizations while applying the firm’s values-based screening to exclude companies in weapons, tobacco, abortion services, and other sectors.

Eventide scales its values philosophy across the full U.S. equity market with ESUM. Not just small-cap, but the full spectrum: mega-cap tech, large financial institutions, mid-cap industrials, everything that passes the screens. The fund is actively managed, so holdings are selected by Eventide’s team rather than mechanically tracking an index. The portfolio typically runs 100–150 stocks — broad enough to qualify as diversified, concentrated enough to reflect genuine management conviction.

The index-free structure means ESUM does not benchmark itself to the S&P 500 or the total market index. It benchmarks instead to its own definitions of quality plus values fit. Expense ratio is correspondingly higher than a passive total-market alternative, which demands the same logic: can active selection and values screening beat a passive core-market portfolio? Eventide’s answer is that the discipline of both quality and ethical criteria surfaces superior businesses across market-cap tiers — a claim the track record either validates or does not.

Holding patterns tell the story. ESUM owns household names — mega-cap technology, healthcare, consumer staples that meet the values bar — plus smaller growers that fit the profile. Sectors screened out entirely are gone: weapons, tobacco, abortion. Financial institutions are in the portfolio if their practices pass review; banks with strong governance and no egregious compliance issues appear. The absence of sectors that comprise meaningful chunks of the broad market (military contractors, tobacco manufacturers) means ESUM’s composition diverges structurally from the market-cap-weighted index. When those excluded sectors perform well, the fund lags; when they underperform, the fund may outpace.

Turnover is moderate. Eventide does not chase performance or trade aggressively; the fund holds positions for reasonable periods and rotates based on fundamental assessment and values alignment. Dividend yield tends to reflect the portfolio’s blend of income-paying blue chips and growth names, skewed toward the blue-chip side since smaller growers often reinvest rather than distribute. Tax efficiency is a secondary consideration given the active overlay, but not neglected.

The real tension: a broad, actively managed values fund competes directly against the lowest-cost passive total-market ETFs, which charge a few basis points and track the entire U.S. opportunity set. For ESUM to justify its fee, it must deliver not just returns, but a values-aligned portfolio and conviction selection that a low-cost index cannot. The bet is that Eventide’s managers find overlooked quality among large caps and across sizes, and that the values screening does not systematically harm performance. For someone hunting a single broad U.S. equity holding that combines diversification with moral convictions, ESUM is the vehicle. For someone indifferent to values alignment and price-sensitive, the index fund wins on cost.

Research approach: compare ESUM’s three and five-year returns against the S&P 500 and a total-market index fund. Does Eventide’s active selection justify the expense ratio gap? Download the fact sheet to see current top holdings and sector weightings — note what is absent. Understand which values screens matter most to you. Read the prospectus for the exact exclusion criteria. Track the portfolio’s concentration: is it truly broad or drifting concentrated? Watch turnover for signs of overtrading. If the management team is stable, continuity matters; if key figures depart, the fund’s future character is uncertain. Finally, settle the personal question: does ethical alignment matter enough to you to accept active-management risk and fees above the passive cost floor?